Linden Advisors LP Invests $8.45 Million in GP-Act III Acquisition Corp. $GPAT

Linden Advisors LP purchased a new position in GP-Act III Acquisition Corp. (NASDAQ:GPATFree Report) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 797,584 shares of the company’s stock, valued at approximately $8,454,000.

A number of other hedge funds have also recently bought and sold shares of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in GP-Act III Acquisition during the 2nd quarter worth approximately $2,638,000. Meteora Capital LLC bought a new stake in shares of GP-Act III Acquisition in the 2nd quarter worth about $20,330,000. Radcliffe Capital Management L.P. lifted its position in shares of GP-Act III Acquisition by 287.8% during the third quarter. Radcliffe Capital Management L.P. now owns 572,895 shares of the company’s stock worth $6,073,000 after purchasing an additional 425,152 shares during the last quarter. Wolverine Asset Management LLC increased its holdings in GP-Act III Acquisition by 90.6% in the third quarter. Wolverine Asset Management LLC now owns 954,866 shares of the company’s stock valued at $10,122,000 after buying an additional 453,866 shares during the last quarter. Finally, Clear Street LLC increased its holdings in GP-Act III Acquisition by 8,429.8% in the second quarter. Clear Street LLC now owns 10,321 shares of the company’s stock valued at $109,000 after buying an additional 10,200 shares during the last quarter.

GP-Act III Acquisition Stock Up 0.1%

NASDAQ GPAT opened at $10.79 on Tuesday. GP-Act III Acquisition Corp. has a one year low of $10.27 and a one year high of $10.80. The company has a 50-day simple moving average of $10.75 and a 200-day simple moving average of $10.68.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of GP-Act III Acquisition in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Get Our Latest Research Report on GPAT

About GP-Act III Acquisition

(Free Report)

GP-Act III Acquisition Corp is a special purpose acquisition company organized as a Delaware corporation that completed its initial public offering in 2021. As a blank-check company, it has no commercial operations of its own and was formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

The company’s primary business activity is to identify and acquire a target company in sectors such as technology, business services, healthcare or other high-growth industries.

Featured Stories

Want to see what other hedge funds are holding GPAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GP-Act III Acquisition Corp. (NASDAQ:GPATFree Report).

Institutional Ownership by Quarter for GP-Act III Acquisition (NASDAQ:GPAT)

Receive News & Ratings for GP-Act III Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GP-Act III Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.